The rational design of
metal-based complexes is an effective strategy for the discovery of potent sensitizers for use in
cancer radiotherapy. In this study, we synthesized three
ruthenium complexes containing
bis-benzimidazole derivatives: Ru(
bbp)Cl3 (1), [Ru(
bbp)2 ]Cl2 (2 a) (in which
bbp=2,6-bis(benzimidazol-1-yl)
pyridine), and [Ru(
bbp)2]Cl2 (2 b) (where
bbp=2,6-bis-(6-nitrobenzimidazol-2-yl)
pyridine). We evaluated their radiosensitization capacities in vitro and mechanisms of action. Complex 2 b was found to be particularly effective in sensitizing human
melanoma A375 cells toward radiation, with a sensitivity enhancement ratio of 2.4. Along with this potency, complex 2 b exhibited a high degree of selectivity between human
cancer and normal cells. Mechanistic studies revealed that 2 b promotes radiation-induced accumulation of intracellular
reactive oxygen species (ROS) by reacting with cellular
glutathione (GSH) and then causing
DNA stand breaks. The subsequent DNA damage induces phosphorylation of p53 (p-p53) and upregulates the expression levels of p21, which inhibits the expression of
cyclin-B, leading to G2M arrest. Moreover, p-p53 activates caspases-3 and -8, triggers cleavage of
poly(ADP-ribose) polymerase (PARP), finally resulting in apoptosis. Taken together, the results of this study provide a strategy for the design of
ruthenium-based radiosensitizers for use in
cancer therapy.